| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,490,000 |
| Market
Cap: |
49.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4088 - $8.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verrica Pharmaceuticals is a dermatology therapeutics company focused on the development and commercialization of treatments for people living with skin diseases. Co.'s primary product candidate, VP-102, is a proprietary drug-device combination of its topical solution of cantharidin, a naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. Co. is initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
24,325,841 |
26,586,040 |
| Total Buy Value |
$0 |
$0 |
$0 |
$13,507,039 |
| Total People Bought |
0 |
0 |
3 |
4 |
| Total Buy Transactions |
0 |
0 |
4 |
14 |
| Total Shares Sold |
0 |
4,315 |
249,384 |
537,992 |
| Total Sell Value |
$0 |
$2,805 |
$1,080,007 |
$2,215,220 |
| Total People Sold |
0 |
1 |
5 |
5 |
| Total Sell Transactions |
0 |
1 |
19 |
33 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Corcoran Gavin |
|
– • – |
2025-03-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20 |
|
18% |
|
| Hayes Christopher G. |
CHIEF LEGAL OFFICER |
• – – |
2025-03-17 |
4 |
S |
$0.65 |
$2,805 |
D/D |
(4,315) |
176,458 |
|
20% |
|
| Zawitz David |
Chief Operating Officer |
• – – |
2024-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
110,000 |
|
-51% |
|
| Stalfort Sean |
|
– • – |
2024-11-26 |
4 |
GA |
$0.00 |
$0 |
D/D |
50,000 |
1,873,800 |
|
- |
|
| Rieger Jayson |
CEO and President |
• • – |
2024-11-26 |
4 |
GA |
$0.00 |
$0 |
D/D |
50,000 |
882,826 |
|
- |
|
| Manning Paul B |
|
– • • |
2024-11-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
450,000 |
25,828,094 |
|
- |
|
| Stalfort Sean |
|
– • – |
2024-11-22 |
4 |
B |
$0.00 |
$0 |
D/D |
1,123,595 |
1,823,800 |
0.01 |
-35% |
|
| Rieger Jayson |
CEO and President |
• • – |
2024-11-22 |
4 |
B |
$0.00 |
$0 |
D/D |
280,898 |
832,826 |
0.01 |
-35% |
|
| Manning Paul B |
|
– • • |
2024-11-22 |
4 |
B |
$0.00 |
$0 |
I/I |
4,494,382 |
5,976,101 |
0.01 |
-35% |
|
| Manning Paul B |
|
– • • |
2024-11-22 |
4 |
B |
$0.00 |
$0 |
D/D |
18,426,966 |
26,278,094 |
0.01 |
-35% |
|
| Kirby John J. |
Interim CFO |
• – – |
2024-11-06 |
4 |
A |
$0.00 |
$0 |
D/D |
54,267 |
54,267 |
|
- |
|
| Rieger Jayson |
CEO and President |
• • – |
2024-11-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,055 |
|
-22% |
|
| Rieger Jayson |
CEO and President |
• • – |
2024-11-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
551,928 |
|
-22% |
|
| Manning Paul B |
|
– • • |
2024-09-19 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,675,611 |
891,870 |
|
- |
|
| Manning Paul B |
|
– • • |
2024-09-19 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,675,611 |
0 |
|
- |
|
| White Ted |
PRESIDENT AND CEO |
• • – |
2024-08-27 |
4 |
S |
$2.46 |
$22,192 |
D/D |
(9,021) |
215,967 |
|
73% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2024-08-27 |
4 |
S |
$2.46 |
$8,858 |
D/D |
(3,601) |
94,261 |
|
73% |
|
| Kohler Terry |
CHIEF FINANCIAL OFFICER |
• – – |
2024-08-27 |
4 |
S |
$2.46 |
$19,432 |
D/D |
(7,899) |
44,697 |
|
73% |
|
| Bonaccorso Joe |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-08-27 |
4 |
S |
$2.46 |
$22,123 |
D/D |
(8,993) |
73,114 |
|
73% |
|
| Hayes Christopher G. |
CHIEF LEGAL OFFICER |
• – – |
2024-08-27 |
4 |
S |
$2.46 |
$23,444 |
D/D |
(9,530) |
105,773 |
|
73% |
|
| White Ted |
PRESIDENT AND CEO |
• • – |
2024-08-26 |
4 |
S |
$2.66 |
$66,444 |
D/D |
(24,979) |
224,988 |
|
73% |
|
| Goldenberg Gary |
Chief Medical Officer |
• – – |
2024-08-26 |
4 |
S |
$2.66 |
$26,302 |
D/D |
(9,888) |
97,862 |
|
73% |
|
| Kohler Terry |
CHIEF FINANCIAL OFFICER |
• – – |
2024-08-26 |
4 |
S |
$2.66 |
$58,041 |
D/D |
(21,820) |
52,596 |
|
73% |
|
| Bonaccorso Joe |
CHIEF COMMERCIAL OFFICER |
• – – |
2024-08-26 |
4 |
S |
$2.66 |
$65,726 |
D/D |
(24,709) |
82,107 |
|
73% |
|
| Hayes Christopher G. |
CHIEF LEGAL OFFICER |
• – – |
2024-08-26 |
4 |
S |
$2.66 |
$69,647 |
D/D |
(26,183) |
115,303 |
|
73% |
|
284 Records found
|
|
Page 1 of 12 |
|
|
0.01 (1.44%) 
